eMedicine Specialties > Dermatology > Malignant Neoplasms
Bowen Disease: Follow-up
Updated: Jul 15, 2008
Follow-up
Further Outpatient Care
- Patients with a history of any type of skin cancer should be evaluated with a total body skin examination every 6-12 months.
Deterrence/Prevention
- Counsel at-risk individuals in the use of sunscreens, photoprotective clothing, and other measures to minimize further actinic damage. Frequent and routine screening should also be stressed to these patients.
Prognosis
- The prognosis for patients with Bowen disease is excellent.
Patient Education
- Patients with a history of Bowen disease should be counseled on safe sun behavior, to include avoiding the sun when it is most intense (between 10 am and 4 pm), wearing hats and other sun protective clothing, and using a dual-spectrum sunscreen with an SPF of 15 or higher.
- For excellent patient education resources, visit eMedicine's Cancer and Tumors Center and Burns Center. Also, see eMedicine's patient education articles Skin Cancer, Skin Biopsy, and Sunburn.
Miscellaneous
Medicolegal Pitfalls
- A failure to recognize Bowen disease or to perform a biopsy in patients suspected of having Bowen disease leads to a delay in treatment. A high degree of suspicion is needed in both sun-exposed and non sun-exposed areas of the skin.
- Surgery for patients with Bowen disease may cause bleeding, scarring, infection, deformity, and nerve damage. Discussing these risks with the patient prior to surgery is important.
- Topical therapy of Bowen disease may result in recurrence or partial treatment, necessitating further biopsy and possible further surgical intervention with attendant risks as above.
Special Concerns
- Rule out an invasive SCC.
More on Bowen Disease |
| Overview: Bowen Disease |
| Differential Diagnoses & Workup: Bowen Disease |
| Treatment & Medication: Bowen Disease |
Follow-up: Bowen Disease |
| Multimedia: Bowen Disease |
| References |
| « Previous Page | Next Page » |
References
Arbesman H, Ransohoff DF. Is Bowen's disease a predictor for the development of internal malignancy? A methodological critique of the literature. JAMA. Jan 23-30 1987;257(4):516-8. [Medline].
Graham JH, Helwig EB. Bowen's disease and its relationship to systemic cancer. AMA Arch Derm. Aug 1959;80(2):133-59. [Medline].
Jaeger AB, Gramkow A, Hjalgrim H, Melbye M, Frisch M. Bowen disease and risk of subsequent malignant neoplasms: a population-based cohort study of 1147 patients. Arch Dermatol. Jul 1999;135(7):790-3. [Medline].
Poole S, Fenske NA. Cutaneous markers of internal malignancy. II. Paraneoplastic dermatoses and environmental carcinogens. J Am Acad Dermatol. Feb 1993;28(2 Pt 1):147-64. [Medline].
Reizner GT, Chuang TY, Elpern DJ, Stone JL, Farmer ER. Bowen's disease (squamous cell carcinoma in situ) in Kauai, Hawaii. A population-based incidence report. J Am Acad Dermatol. Oct 1994;31(4):596-600. [Medline].
Saxena A, Kasper DA, Campanelli CD, Lee JB, Humphreys TR, Webster GF. Pigmented Bowen's disease clinically mimicking melanoma of the nail. Dermatol Surg. Dec 2006;32(12):1522-5. [Medline].
Bargman H, Hochman J. Topical treatment of Bowen's disease with 5-Fluorouracil. J Cutan Med Surg. Mar-Apr 2003;7(2):101-5. [Medline].
Fulton JE Jr, Carter DM, Hurley HJ. Treatment of Bowen's disease with topical 5-fluorouracil under occlusion. Arch Dermatol. Feb 1968;97(2):178-80. [Medline].
Sturm HM. Bowen's disease and 5-fluorouracil. J Am Acad Dermatol. Dec 1979;1(6):513-22. [Medline].
Welch ML, Grabski WJ, McCollough ML, Skelton HG, Smith KJ, Menon PA, et al. 5-fluorouracil iontophoretic therapy for Bowen's disease. J Am Acad Dermatol. Jun 1997;36(6 Pt 1):956-8. [Medline].
Mackenzie-Wood A, Kossard S, de Launey J, Wilkinson B, Owens ML. Imiquimod 5% cream in the treatment of Bowen's disease. J Am Acad Dermatol. Mar 2001;44(3):462-70. [Medline].
van Egmond S, Hoedemaker C, Sinclair R. Successful treatment of perianal Bowen's disease with imiquimod. Int J Dermatol. Mar 2007;46(3):318-9. [Medline].
Fernández-Vozmediano J, Armario-Hita J. Infiltrative squamous cell carcinoma on the scalp after treatment with 5% imiquimod cream. J Am Acad Dermatol. Apr 2005;52(4):716-7. [Medline].
Dupree MT, Kiteley RA, Weismantle K, Panos R, Johnstone PA. Radiation therapy for Bowen's disease: lessons for lesions of the lower extremity. J Am Acad Dermatol. Sep 2001;45(3):401-4. [Medline].
Braathen LR, Szeimies RM, Basset-Seguin N, Bissonnette R, Foley P, Pariser D, et al. Guidelines on the use of photodynamic therapy for nonmelanoma skin cancer: an international consensus. International Society for Photodynamic Therapy in Dermatology, 2005. J Am Acad Dermatol. Jan 2007;56(1):125-43. [Medline].
Jones CM, Mang T, Cooper M, Wilson BD, Stoll HL Jr. Photodynamic therapy in the treatment of Bowen's disease. J Am Acad Dermatol. Dec 1992;27(6 Pt 1):979-82. [Medline].
Leibovitch I, Huilgol SC, Selva D, Richards S, Paver R. Cutaneous squamous carcinoma in situ (Bowen's disease): treatment with Mohs micrographic surgery. J Am Acad Dermatol. Jun 2005;52(6):997-1002. [Medline].
Tantikun N. Treatment of Bowen's disease of the digit with carbon dioxide laser. J Am Acad Dermatol. Dec 2000;43(6):1080-3. [Medline].
Arnold HL, Odom RB, James WD. Bowen's disease. In: Arnold HL, Andrews GC, Odom RB, James WB, eds. Andrews' Diseases of the Skin. 8th ed. Philadelphia, Pa: WB Saunders; 1990:783-5.
Cox NH, Eedy DJ, Morton CA. Guidelines for management of Bowen's disease: 2006 update. Br J Dermatol. Jan 2007;156(1):11-21. [Medline].
Gard D. Nonpigmented premalignant lesions of the skin. Clin Plast Surg. Apr 1987;14(2):413-23. [Medline].
Lee MM, Wick MM. Bowen's disease. Clin Dermatol. Jan-Mar 1993;11(1):43-6. [Medline].
Ragi G, Turner MS, Klein LE, Stoll HL Jr. Pigmented Bowen's disease and review of 420 Bowen's disease lesions. J Dermatol Surg Oncol. Jul 1988;14(7):765-9. [Medline].
Further Reading
Keywords
squamous cell carcinoma in situ, SCC, human papilloma virus 16, HPV 16, human papillomavirus 16
Follow-up: Bowen Disease